CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade SpringWorks Therapeutics, Inc. - SWTX CFD

41.82
5.17%
Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.14
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023679 %
Charges from full value of position ($-4.50)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023679%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001457 %
Charges from full value of position ($0.28)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001457%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 44.1
Open 43.36
1-Year Change -12.01%
Day's Range 41.01 - 43.46
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 1, 2025 41.82 -1.89 -4.32% 43.71 44.01 40.91
Mar 31, 2025 44.10 -1.49 -3.27% 45.59 45.64 43.76
Mar 28, 2025 47.34 -0.11 -0.23% 47.45 47.79 45.95
Mar 27, 2025 47.42 1.00 2.15% 46.42 47.81 46.10
Mar 26, 2025 46.39 -0.82 -1.74% 47.21 47.21 45.80
Mar 25, 2025 47.17 -1.04 -2.16% 48.21 48.35 46.93
Mar 24, 2025 48.43 -1.42 -2.85% 49.85 50.22 48.31
Mar 21, 2025 49.84 -0.49 -0.97% 50.33 50.64 49.46
Mar 20, 2025 51.01 0.90 1.80% 50.11 51.35 50.11
Mar 19, 2025 50.58 1.89 3.88% 48.69 50.82 48.69
Mar 18, 2025 48.96 -0.17 -0.35% 49.13 50.20 48.56
Mar 17, 2025 49.76 -1.04 -2.05% 50.80 50.80 47.60
Mar 14, 2025 51.10 1.15 2.30% 49.95 51.44 48.84
Mar 13, 2025 49.69 -1.08 -2.13% 50.77 51.23 48.59
Mar 12, 2025 50.83 -0.18 -0.35% 51.01 52.18 50.21
Mar 11, 2025 50.81 2.76 5.74% 48.05 51.59 47.33
Mar 10, 2025 48.38 0.69 1.45% 47.69 49.18 46.58
Mar 7, 2025 49.45 -1.74 -3.40% 51.19 53.08 49.34
Mar 6, 2025 51.25 -0.31 -0.60% 51.56 53.45 50.98
Mar 5, 2025 50.51 -0.99 -1.92% 51.50 51.98 49.75

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

SpringWorks Therapeutics, Inc. Company profile

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. It has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SpringWorks Therapeutics Inc revenues decreased from $35M to $0K. Net loss increased from $45.6M to $173.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Biopharmaceutical segment loss increase from $46.3M to $173.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.05 to -$3.59.

Industry: Bio Therapeutic Drugs

100 Washington Blvd
STAMFORD
CONNECTICUT 06902-9302
US

People also watch

ETH/USD

1,858.05 Price
-2.910% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

BTC/USD

84,222.40 Price
-1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

US100

19,399.10 Price
-0.090% 1D Chg, %
Long position overnight fee -0.0237%
Short position overnight fee 0.0015%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

2.08 Price
-3.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01037

Still looking for a broker you can trust?

Join the 710,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading